Canvas Inc. is a drug discovery bioventure company focused on the research and development of anticancer agents. The company develops its own pipeline of drug candidates based on its proprietary drug discovery platform ('drug discovery engine'), with a lead compound CBP501—a novel immune activator targeting cancer immunology—currently advancing through Phase 2 clinical trials for pancreatic cancer in combination with immune checkpoint inhibitors. Canvas also out-licenses compounds such as CBS9106 (felezonexor), a reversible CRM1 inhibitor, to global pharmaceutical partners including Stemline Therapeutics.
Free demo (no time limit, up to 10 companies). Explore Comps, DCF, LBO, WACC on every screen. Excel export is on the paid plan.
Free Demo (No Time Limit, 10 Companies) →Canvas Inc. is a drug discovery bioventure company focused on the research and development of anticancer agents. The company develops its own pipeline of drug candidates based on its proprietary drug discovery platform ('drug discovery engine'), with a lead compound CBP501—a novel immune activator targeting cancer immunology—currently advancing through Phase 2 clinical trials for pancreatic cancer in combination with immune checkpoint inhibitors. Canvas also out-licenses compounds such as CBS9106 (felezonexor), a reversible CRM1 inhibitor, to global pharmaceutical partners including Stemline Therapeutics.
Free demo (no time limit, up to 10 companies). Explore Comps, DCF, LBO, WACC on every screen. Excel export is on the paid plan.
Free Demo (No Time Limit, 10 Companies) →